Advana Science announced that Rick Kaiser, a leading industry veteran, has been named Vice President of Sales. Kaiser brings over 30 years of sales experience in the pharmaceutical and nutraceutical industries working with leading companies such as Bristol-Myers Squibb, Ivax Pharmaceuticals and Nutrition 21, Inc. Kaiser will be responsible for execution of Advana’s commercialization model of its new biotechnology scientific discoveries in beta amyloid plaque reduction linked to major degenerative diseases, including Alzheimer's disease and Type 2 diabetes for nutraceutical applications.
"I am pleased to be working with Rick who has a proven track record for being able to translate robust science into consumer business opportunities”, said Peter Leighton, CEO, Advana Science. "Rick has a long history of successfully growing enterprises and an outstanding reputation among our industry peers," added Leighton.
Advana Science holds the patents to safe, natural compounds that have been shown to intervene early in at-risk populations to prevent beta-amyloid protein deposits and dissolve or disrupt existing beta-amyloid formations. These natural compounds have been isolated from plant materials and Advana will be out licensing its robust IP portfolio for use in nutraceutical and functional food applications for the consumer marketplace.
About Advana Science
Advana Science is a life sciences company focused on developing preventative and early stage solutions for age associated memory loss and cognitive enhancement, and other conditions associated with beta amyloid formation such as Alzheimer’s disease and Type 2 Diabetes. Advana Science oversees a broad portfolio of 42 patents that can be used for break-through nutraceutical products. Specific claims in these patents include memory enhancement, cognitive improvement and amyloid plaque reduction in humans. Advana Science corporate office is located at 12036 115th Ave. NE, Kirkland, WA 98034. (425) 823-0100. www.advanascience.com